General Information of Drug (ID: DM3B1CE)

Drug Name
4-phenylthiazole-2-thiol Drug Info
Synonyms
4-Phenylthiazole-2-thiol; 2103-88-0; 2-Mercapto-4-phenylthiazole; 4-Phenyl-2-thiazolethiol; 4-Phenyl-1,3-thiazole-2-thiol; 2(3H)-Thiazolethione, 4-phenyl-; 4-Phenyl-2-mercaptothiazole; 4-Thiazoline-2-thione, 4-phenyl-; 2-Thiazolethiol, 4-phenyl-; 4-phenyl-thiazole-2-thiol; CHEMBL571436; 4-Phenylthiazole-2(3H)-thione; NSC 678; CYCKHTAVNBPQDB-UHFFFAOYSA-N; EINECS 218-274-7; 4-phenyl-3H-1,3-thiazole-2-thione; NSC678; zlchem 830; AC1MHDCC; ACMC-1CJ8W; 2-mercapto-4-phenylthiazol; MLS001006837; SCHEMBL178051; SCHEMBL11460891
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3000729
ChEBI ID
CHEBI:109516
CAS Number
CAS 2103-88-0
TTD Drug ID
DM3B1CE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [2]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [3]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [4]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [5]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [4]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [1]

References

1 Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89.
2 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
3 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Incyte. Product Development Pipeline.
6 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
7 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)